CASP6 Primary Antibody

Item Information
Catalog # Size/Concentration Price
31730 100ug $341.00
Entrez GeneID839
FormulationPurified antibody in PBS with 0.05% sodium azide
ImmunogenPurified recombinant fragment of human CASP6 (AA: 194–293) expressed in E. Coli.
ICC (Immunocytochemistry)1/100- 1/500
FCM (Flow Cytometry)1/200 - 1/400
WB (Western Blot)1/500 - 1/2000
(AA: 194–293) expressed in E. Coli.

Contact us to order


Figure 1: Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)

Cell Culture Products

Figure 2: Western blot analysis using CASP6 mAb against human CASP6 (AA: 194–293) recombinant protein. (Expected MW is 37.2 kDa)

Cell Culture Products

Figure 3: Western blot analysis using CASP6 mAb against HEK293 (1) and CASP6 (AA: 194–293)-hIgGFc transfected HEK293 (2) cell lysate.

Cell Culture Products

Figure 4: Immunofluorescence analysis of Hela cells using CASP6 mouse mAb (green). Blue: DRAQ5 fluorescent DNA dye. Red: Actin filaments have been labeled with Alexa Fluor- 555 phalloidin. Secondary antibody from Fisher (Cat#: 35503)

Cell Culture Products

Figure 5: Flow cytometric analysis of Hela cells using CASP6 mouse mAb (green) and negative control (red).

Cell Culture Products
Product Overview

This gene encodes a member of the cysteine-aspartic acid protease (caspase) family of enzymes. Sequential activation of caspases plays a central role in the execution-phase of cell apoptosis. Caspases exist as inactive proenzymes which undergo proteolytic processing at conserved aspartic acid residues to produce two subunits, large and small, that dimerize to form the active enzyme. This protein is processed by caspases 7, 8 and 10, and is thought to function as a downstream enzyme in the caspase activation cascade. Alternative splicing of this gene results in multiple transcript variants that encode different isoforms.

References (references)
References (references) 1.Biochemistry. 2017 Aug 29;56(34):4568-4577.
2.Acta Neuropathol Commun. 2016 Dec 8;4(1):127.

Please view FAQs here